Supernus Pharmaceuticals Engages in Key Neuropsychiatry Event

Supernus Pharmaceuticals to Participate in Neuropsychiatry Summit

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dedicated biopharmaceutical company engaged in innovative treatments for central nervous system (CNS) disorders, is gearing up for an important virtual event. The company's President and CEO, Jack Khattar, is set to participate in a fireside chat during the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit.

Event Details and Significance

This event will take place on an upcoming Thursday morning in September. Mr. Khattar's participation signifies Supernus Pharmaceuticals' ongoing commitment to advancing the understanding of neuropsychiatric mechanisms. His insights are expected to center around the company’s role in developing effective therapies for CNS conditions.

Live Webcast Access and Archive

A live broadcast of the discussion will be available for public viewing, providing an opportunity for stakeholders and interested parties to gain insights into the latest developments in the field of neuropsychiatry. Following the event, an archived version of the session will also be accessible on the company’s website for 60 days, ensuring that those unable to attend live can still benefit from the valuable information shared.

Supernus Pharmaceuticals: A Focus on CNS Diseases

As a forward-looking biopharmaceutical entity, Supernus Pharmaceuticals focuses intently on the treatment of CNS diseases. Their diverse range of products includes treatments for various conditions such as epilepsy, migraines, attention-deficit/hyperactivity disorder (ADHD), and more recently, therapies targeting hypomobility in Parkinson's disease (PD) and chronic sialorrhea.

Innovative Neuroscience Portfolio

With a robust neuroscience portfolio, Supernus is dedicated to bringing new therapies to patients suffering from challenging CNS disorders. Their commitment extends beyond merely commercializing existing treatments; they are also pioneering new treatment avenues for epilepsy and depression, among other critical conditions.

Future Product Development

The company is ambitiously expanding its pipeline with a variety of novel product candidates designed to address unmet medical needs in CNS disease treatment. The research and development team is actively engaging in clinical trials aimed at evaluating the safety and efficacy of these new therapies.

Commitment to Community and Stakeholders

Supernus Pharmaceuticals strives to maintain strong relationships with healthcare professionals, investors, and the community. By participating in high-profile summits and presenting at industry conferences, the company enhances awareness of CNS disorders and the importance of timely and effective treatment options.

Investors and stakeholders interested in the detailed offerings of Supernus Pharmaceuticals can find more information through the company’s official platforms, ensuring they stay updated with the latest developments and insights into their innovative pipeline.

Contact Information

For inquiries, Supernus Pharmaceuticals encourages direct communication with its executive team:

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

Investor Relations Contact:

Peter Vozzo
ICR Westwicke
(443) 213-0505
peter.vozzo@westwicke.com

Frequently Asked Questions

What is the focus of Supernus Pharmaceuticals?

Supernus Pharmaceuticals focuses on developing treatments for various central nervous system diseases.

Who will represent Supernus Pharmaceuticals at the event?

Jack Khattar, the CEO, will represent the company in the upcoming neuropsychiatry summit.

Where can I access the live webcast of the event?

The webcast will be accessible on Supernus Pharmaceuticals' website on the day of the event.

What types of diseases does Supernus target?

The company targets CNS diseases such as epilepsy, migraines, ADHD, and conditions associated with Parkinson's disease.

How can I learn more about Supernus Pharmaceuticals?

For detailed information about their products and pipeline, visit Supernus Pharmaceuticals’ official website.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.